innate defense regulating peptide 1018

derived from bovine cathelicidin bactenecin

Also Known As:

IDR 1018; IDR-1018; IDR1018; VRLIVAVRIWRR; Val-Arg-Leu-Ile-Val-Ala-Val-Arg-Ile-Trp-Arg-Arg; valyl-arginyl-leucyl-isoleucyl-valyl-alanyl-valyl-arginyl-isoleucyl-tryptophyl-arginyl-arginine

Networked: 16 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Pore Forming Cytotoxic Proteins
      - Antimicrobial Cationic Peptides: 414
        innate defense regulating peptide 1018: 16
- Peptides: 82426
  - Antimicrobial Peptides: 3727
    - Antimicrobial Cationic Peptides: 414
      - innate defense regulating peptide 1018: 16
  - Antimicrobial Cationic Peptides: 414
    - innate defense regulating peptide 1018: 16

Experts

1.	Hancock, Robert E W: 9 articles (12/2020 - 01/2012)
2.	Falsafi, Reza: 2 articles (12/2020 - 01/2013)
3.	Pletzer, Daniel: 2 articles (12/2020 - 10/2020)
4.	González-Curiel, Irma: 2 articles (01/2018 - 01/2013)
5.	Rivas-Santiago, Bruno: 2 articles (01/2018 - 01/2013)
6.	de la Fuente-Núñez, César: 2 articles (01/2017 - 05/2015)
7.	Fjell, Christopher D: 2 articles (03/2014 - 01/2013)
8.	Afacan, Nicole: 2 articles (01/2013 - 01/2012)
9.	Belanger, Corrie R: 1 article (12/2020)
10.	Dhillon, Bhavjinder Kaur: 1 article (12/2020)

Related Diseases

1.	Wounds and Injuries (Trauma) 01/01/2023 - "Likewise, in both melanocytes and keratinocytes, the treatment with synoeca-MP/IDR-1018 combination induces cell proliferation and migration, while in a 3D human skin equivalent model, it can accelerate wound reepithelization. " 01/01/2012 - "It is anticipated that the wound healing activities of IDR-1018 can be attributed to modulation of host immune pathways that are suppressed in diabetic wounds and provide further evidence of the multiple immunomodulatory activities of IDR-1018." 01/01/2017 - "Altogether, the current study suggests a novel immunomodulatory role of IDR-1018 through its ability to recruit and activate human mast cells at the sites of inflammation and wounds. " 01/01/2023 - "In the present study, we used human skin cells and a 3D skin equivalent models to analyze the potential of the IDR-1018 peptide to attenuate the cytotoxicity of synoeca-MP, as well as the influence of synoeca-MP/IDR-1018 combination on cell proliferation, regenerative processes, and wound repair. "
2.	Inflammation (Inflammations) 10/01/2020 - "The inhalation of NAC/PLGA-MPP encapsulated with IDR-1018 significantly reduced (p < .05) bacterial load (up to ~3.02LogCFU/ml) and inflammation in lungs in a mouse model of TB compared to untreated and blank treated animals in 6 weeks of daily dose. " 01/01/2017 - "Altogether, the current study suggests a novel immunomodulatory role of IDR-1018 through its ability to recruit and activate human mast cells at the sites of inflammation and wounds. " 10/01/2020 - "Cyclic Derivative of Host-Defense Peptide IDR-1018 Improves Proteolytic Stability, Suppresses Inflammation, and Enhances In Vivo Activity." 03/01/2014 - "To gain insight into peptide-mediated effects on LPS-induced inflammation and neuroprotective mechanisms, global cerebral gene expression patterns were analyzed in pups that were treated with IDR-1018 either 4 hours before LPS or 3 hours after LPS+HI. "
3.	Infections 10/21/2022 - "When applied to different infection models focused on intracellularly surviving bacteria, only IDR-1018 showed a consistent reduction in macrophage bacterial uptake. " 09/01/2015 - "IDR-1018 is potentially useful to reduce orthopaedic infections by directly killing bacteria and by recruiting macrophages to the infection site. " 09/01/2015 - "IDR-1018 demonstrated antimicrobial activity by directly killing S aureus even in the presence of physiologic ion levels, increasing recruitment of macrophages to the site of infections by 40% (p = 0.036) and accelerating S aureus clearance in vivo (p = 0.008) with a 2.6-fold decrease in bacterial bioburden on Day 7 postimplantation. " 09/01/2015 - "We sought (1) to more fully characterize the immunomodulatory effects of IDR-1018, especially in response to Staphylococcus aureus; and (2) to determine whether IDR-1018 decreases S aureus infection of orthopaedic implants in mice and thereby protects the implants from failure to osseointegrate. " 09/01/2015 - "However, IDRs have not been tested on orthopaedic infections and the immunomodulatory effects of IDR-1018 have only been characterized in response to lipopolysacharide, which is exclusively produced by Gram-negative bacteria. "
4.	Bacterial Infections (Bacterial Infection) 10/01/2020 - "The findings describe different routes to the creation of enzymatically stable mimetics of IDR-1018 and identify a promising new cyclic analogue against bacterial infections." 05/01/2015 - "Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections."
5.	Candidemia 01/01/2017 - "Thus, IDR-1018 was able to protect against murine experimental candidemia and has the potential as an adjunctive therapy." 01/01/2017 - "Mice treated with IDR-1018 at 10 mg · kg-1 of body weight had an increased survival rate in the candidemia model compared with phosphate-buffered saline (PBS)-treated mice, together with a diminished kidney fungal burden. "

Related Drugs and Biologics

1.	innate defense regulating peptide 1018
2.	Peptides (Polypeptides)
3.	Antimicrobial Cationic Peptides
4.	Cytokines
5.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
6.	Chemokines
7.	Interleukin-8 (Interleukin 8)
8.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
9.	Leukotrienes
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Therapeutics